5384-55-4

Upstream product

• 22618-22-0 2,3-dimethylphenyl acetate 
• 526-75-0 2,3-Dimethylphenol 
• 108-24-7 acetic anhydride 

Downstream Products

• 2785-76-4 3,4-dimethylbenzene-1,2-diol 
• 18441-55-9 6-ethyl-2,3-dimethyl-phenol 
• 147623-18-5 1-(2-methoxy-3,4-dimethylphenyl)ethanone 
• 118538-98-0 acetic acid 2-methoxy-3,4-dimethylphenyl ester 
• 248252-69-9 1,2-dimethoxy-3,4-dimethylbenzene 
• 55004-75-6 7,8-dimethyl-4-hydroxy-2H-1-benzopyran-2-one 
• 879564-30-4 7,8-dimethyl-4-oxo-N-(4-sulfamoylphenethyl)-4H-chromene-2-carboxamide 
• 526-75-0 2,3-Dimethylphenol 

Relevant academic research and scientific papers

BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR

The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.

REARRANGEMENT OF DIMETHYLPHENYLACYLATES USING ZEOLITES

The present invention relates to a Fries rearrangement of specific dimethylphenylacylates to form the desired respective hydroxyaryl ketones having two methyl groups bound to the aromatic ring. It has been found that the process is surprisingly very specific in view of the number and position of the methyl group(s) bound to the aromatic ring.

Substrate substitution effects in the Fries rearrangement of aryl esters over zeolite catalysts

The catalytic transformation of aryl esters to hydroxyacetophenones via Fries rearrangement over solid acids is of interest to avoid the use of corrosive and toxic Lewis and Br?nsted acids traditionally applied. Microporous zeolites are known to catalyze the reaction of simple substrates such as phenyl acetate, but their application to substituted derivatives has received limited attention. To refine structure-activity relationships, here we examine the impact of various parameters including the solvent polarity, water content, acidic properties, and framework type on the reaction scheme in the Fries rearrangement of p-tolyl acetate over common solid acids. The results confirm the importance of providing a high concentration of accessible Br?nsted acid sites, with beta zeolites exhibiting the best performance. Extension of the substrate scope by substituting methyl groups in multiple positions identifies a framework-dependent effect on the rearrangement chemistry and highlights the potential for the transformation of dimethylphenyl acetates. Kinetic studies show that the major competitive path of cleavage of the ester C-O bond usually occurs in parallel to the Fries rearrangement. The possibility of sequentially acylating the resulting phenol depends on the substrate and reaction conditions.

MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: Quinone oxidoreductase-1 (NQO1)

The synthesis is reported here of two novel series of inhibitors of human NAD(P)H quinone oxidoreductase-1 (NQO1), an enzyme overexpressed in several types of tumor cell. The first series comprises substituted symmetric dicoumarol analogues; the second series contains hybrid compounds where one 4-hydroxycoumarin systemis replaced by a different aromatic moiety. Several compounds show equivalent or improved NQO1 inhibition over dicoumarol, both in the presence and in the absence of added protein. Further, correlation is demonstrated between the ability of these agents to inhibit NQO1 and computed binding affinity. We have solved the crystal structure of NQO1 complexed to a hybrid compound and find good agreement with the in silico model. For both MIA PaCa-2 pancreatic tumor cells and HCT116 colon cancer cells, dicoumarol shows the greatest toxicity of all compounds. Thus, we provide a computational, synthetic, and biological platform to generate competitive NQO1 inhibitors with superior pharmacological properties to dicoumarol. This will allow a more definitive study of NQO1 activity in cells, in particular, its drug activating/detoxifying properties and ability to modulate oncoprotein stability. 2009 American Chemical Society.

Ion channel modulating agents

The present invention relates to ion channel modulating agents. More particularly, the present invention relates to a particular class of oxime derivatives represented by general formula (I) that has proven useful as modulators of SKCa, IKCa and BKCa channels. In further aspects, the present invention relates to the use of these SK/IK/BK channel modulating agents for the manufacture of medicaments, and pharmaceutical compositions comprising the SK/IK/BK channel modulating agents. The SK/IK/BK channel modulating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK/BK channels.